PhaseV, a leader in applying causal machine learning (ML) for dynamic clinical trial analysis and optimization, has formed a partnership with Israeli biopharma marketplace 9xchange. The collaboration integrates PhaseV’s ML technology into 9xchange's transaction platform, providing its members the ability to retrospectively analyze and optimally design and execute advanced clinical studies.
Anat Naschitz, CEO and co-founder of 9xchange, stated, “Too many deserving drugs never get to patients due to insufficient resource or attention, or objective issues such as suboptimal trial design. The seamless, online and initially anonymous transaction path offered by 9xchange removes friction and unveils unexpected availability and matches, while enabling members to tap into new value through a range of AI/ML technologies. For our members, the PhaseV partnership means new opportunities. Owners can chart a new course for assets lost to trial failure, increase the value at sale and build confidence in a likely outcome. Buyers and investors can conduct due diligence on an asset and circumscribe the cost and probability of success. We build partnerships carefully, and are excited to collaborate with PhaseV, whose team and technology we find very impressive.”
